Bicycle Therapeutics (BCYC)

Executive Summary

Bicycle Therapeutics is a clinical-stage biopharmaceutical company pioneering a novel class of precision-guided therapeutics called Bicycles—fully synthetic, constrained peptides that combine the targeting precision of antibodies with the tissue-penetrating properties of small molecules. The company is focused on intractable solid tumors, with a lead program BT8009 targeting Nectin-4, a clinically validated antigen in urothelial and other cancers. Bicycle's platform offers potential advantages in tumor penetration, rapid clearance, and flexible dosing. The company has completed Phase 1/2 trials for its first-generation Bicycle toxin conjugate (BTC) BT1718 and is advancing next-generation BTCs, including BT5528 targeting EphA2 and BT7480 targeting Nectin-4/CD137 for immuno-oncology combinations. In 2025, Bicycle reported encouraging Phase 1/2 data for BT8009 in urothelial cancer, demonstrating durable responses in a heavily pretreated population. The company plans to initiate a pivotal trial for BT8009 in 2026, with a potential registration path contingent on further data. Additionally, BT7480 is in early-stage clinical development for solid tumors. With a strong cash position and a proprietary platform capable of generating multiple candidates, Bicycle Therapeutics is well-positioned to become a leading solid tumor medicines company. Key upcoming milestones include data from the BT8009 expansion cohorts and initiation of pivotal studies, which will be critical for near-term value inflection.

Upcoming Catalysts (preview)

• Q3 2026BT8009 pivotal trial initiation and interim efficacy data60% success
• Q4 2026BT5528 Phase 1/2 dose escalation data update50% success
• H1 2027BT7480 Phase 1/2 initial safety and efficacy data40% success